A Science and Technology Blog
On January 3, the Indian regulator approved Covaxin for restricted use “under clinical trial mode” as a matter of “abundant caution” even when no interim data of phase-3 trial was…
On January 16, when the mass COVID-19 vaccination programme began in India, only 3,352 sessions were held and 0.19 million people were vaccinated. “The vaccination rate will increase exponentially in…
What are the main challenges in developing and testing booster vaccine doses to address the new variants? Each variant (and many more beyond the first three that have been widely…
In both these cases, the SEC allowed the vaccine manufacturers to use a placebo in the control arm even as two vaccines — Covishield and Covaxin — have been granted…
The sera from people vaccinated with Covaxin were tested against the same strain used for making the vaccine, another strain found in India but different from the one used for…
In a tweet on January 14, the Health Ministry said both Covishield and Covaxin approved for restricted use by the Indian regulator are safe. The Health Ministry released a statement…
True, in the U.S., vaccines from both Pfizer and Moderna are available and recipients, who are health-care workers and nursing home residents, have no option to choose the vaccine. In…
The phase-3 clinical trial of Bharat Biotech’s COVID-19 vaccine, Covaxin, by a private hospital in the Bhopal-based Peoples College of Medical Sciences & Research Centre appears to suffer from serious…
